drugset
drugset / Trial / NCT00878020

Safety Study to Evaluate BMS-830216 in Healthy Subjects

NCT00878020 ↗

Phase 1 Completed 48 enrolled Bristol-Myers Squibb
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the safety profile, tolerability, and pharmacokinetics of single oral doses from 10 mg up to 1200 mg of BMS-830216 (pro-drug of BMS-819881) in healthy subjects

Timeline

Start
2009-05
Primary completion
2009-09
Completion
2009-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator BMS-830216 Small molecule 10 mg Oral
Comparator BMS-830216 Small molecule 30 mg Oral
Comparator BMS-830216 Small molecule 100 mg Oral
Comparator BMS-830216 Small molecule 300 mg Oral
Comparator BMS-830216 Small molecule 600 mg Oral
Comparator BMS-830216 Small molecule 1200 mg Oral

Indications

obesity disorder